Article
Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2018
Coombs Catherine C, Gillis Nancy K, Tan Xianming, Berg Jonathan S, Ball Markus, Balasis Maria E, Montgomery Nathan D, Bolton Kelly L, Parker Joel S, Mesa Tania E, Yoder Sean J, Hayward Michele C, Patel Nirali M, Richards Kristy L, Walko Christine M, Knepper Todd C, Soper John T, Weiss Jared, Grilley-Olson Juneko E, Kim William Y, Earp H Shelton, Levine Ross L, Papaemmanuil Elli, Zehir Ahmet, Hayes D Neil, Padron Eric
Abstract excerpt
PURPOSE: In this era of precision-based medicine, for optimal patient care, results reported from commercial next-generation sequencing (NGS) assays should adequately reflect the burden of somatic mutations in the tumor being sequenced. Here, we sought to determine the prevalence of clonal hematopoiesis leading to possible misattribution of tumor mutation calls on unpaired Foundation Medicine NGS assays....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.